Back to search

Article

A Nomogram for Predicting Mammaprint Results in Women with T1-3N0-1M0 Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor-2-Negative Breast Cancer

2021-08-13

Abstract excerpt

<h4>Purpose: </h4> We aimed to develop a prediction MammaPrint (MMP) genomic risk assessment nomogram model for hormone-receptor-positive and human epidermal growth factor receptor-2 (HER2)-negative breast cancer and minimal axillary burden (N0-1) tumors using clinicopathological factors of patients who underwent an MMP test for decision making regarding adjuvant chemotherapy. <h4>Methods: </h4> A total of 409 T1-...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
bb8de160-295b-5e47-b498-ac22e6797786
DOI
10.21203/rs.3.rs-764423/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
A Nomogram for Predicting Mammaprint Results in Women with T1-3N0-1M0 Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor-2-Negative Breast CancerDOI 10.21203/rs.3.rs-764423/v1
Validation study of a nomogram for predicting probability of low risk of MammaPrint results in women with clinically high-risk breast cancerSemantic proximity
Prediction of the 70-gene signature (MammaPrint) high versus low risk by nomograms among axillary lymph node positive (LN+) and negative (LN-) Chinese breast cancer patients, a retrospective studySemantic proximity
Estimated survival outcomes and absolute chemotherapy treatment benefit using PREDICT Tool® and EndoPredict®, in hormone-positive early-stage breast cancer.Semantic proximity
<p class="MDPI12titleori1" style="mso-line-height-alt: 14.0pt;"><span style="mso-bidi-font-size: 18.0pt; mso-bidi-font-weight: bold;">MammaPrint™ Genetic Signature in the Brazilian Population, Analysis of Results and Clinical Outcomes (AGEMA-BRA) – Real World StudySemantic proximity
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.Semantic proximity
Prognostic and predictive biomarkers with therapeutic targets in breast cancer: A 2022 update on current developments, evidence, and recommendationsSemantic proximity
Deep Learning on Histopathological Images to Predict Breast Cancer Recurrence Risk and Chemotherapy BenefitSemantic proximity
Nomogram prediction of the 70-gene signature (MammaPrint) binary and quartile categorized risk using medical history, imaging features and clinicopathological data among Chinese breast cancer patientsSemantic proximity
MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early‐stage breast cancer patientsSemantic proximity
Adjuvant Chemotherapy Guidance for pT1-3N0-1 Breast Cancer Patients with HR+, HER2- subtype: a study based on SEER databaseSemantic proximity
High concordance of 70-gene recurrence risk signature and 80-gene molecular subtyping signature between core needle biopsy and surgical resection specimens in early-stage breast cancerSemantic proximity
Multimodal histopathologic models stratify hormone receptor-positive early breast cancerSemantic proximity
Select a neighboring publication to make it the new centre.